Anorexia, pain and peripheral neuropathy are associated with a decrease in quality of life in patients with advanced pancreatic cancer receiving outpatient chemotherapy — a retrospective observational study

Table 4 Analysis using a mixed effects model for AEs and risk factors associated with the EQ-5D-5L utility value in patients who received chemotherapy

Factors	Coefficient	95% CI	P value
Nausea	−0.015	−0.046 – 0.015	0.339
Anorexia	−0.043	−0.067 – − 0.019	0.001
Pain	−0.051	− 0.083 – − 0.019	0.002
Fatigue	− 0.001	− 0.025 – 0.024	0.966
Peripheral neuropathy	−0.021	− 0.041 – 0.002	0.035
Dysgeusia	0.015	−0.007 – 0.038	0.197
Female	−0.022	−0.092 – 0.047	0.543
Age (IQR:61.5–75)	−0.016	−0.065 – 0.032	0.524
mGPS (IQR:0–2)	−0.003	−0.034 – 0.028	0.870
Distant metastasis	−0.013	−0.067 – 0.039	0.626
FOLFIRINOX	0.021	−0.026 – 0.068	0.400
NLR (IQR:1.4–3.1)	0.002	−0.005 – 0.009	0.603
CEA, μg/L (IQR:2.8–8.3)	−0.001	−0.002 – 0	0.125
Time from start of first-line chemotherapy, day (IQR:112–386)	−0.007	−0.023 – 0.008	0.365

mGPS modified Glasgow prognostic score, NLR Neutrophil-lymphocyte ratio, CEA Carcinoembryonic antigen, IQR Inter-quartile range (25–75th percentiles)
Coefficient for continuous variables indicate the difference of mean in QOL for the increment in IQR

ISSN: 2055-0294